Puma Biotech's (PBYI) Neratinib Wins Backing From FDA Panel

May 24, 2017 11:47 AM EDT
Get Alerts PBYI Hot Sheet
Price: $1.91 +3.80%

Overall Analyst Rating:
    NEUTRAL (Up Up)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Puma Biotech's (NASDAQ: PBYI) Neratinib won backing from an FDA panel in a 12 to 4 vote supporting the drug's risk-benefit profile.

Trading remains halted.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Hot Corp. News, Hot FDA News, Trading Halts

Related Entities

FDA